Organogenesis Q1 Revenues Decline While Peers Hit $391.9 M and $132.1 M
ORGO•Organogenesis posted first-quarter revenue declines in its advanced wound-care franchise, bucking industry growth as Integra’s top line rose 2.4% to $391.9 million and Bioventus increased revenue 7% to $132.1 million. This underperformance highlights reimbursement headwinds and intensifying competition ahead of ORGO’s clinical catalysts.
1. ORGO Q1 Performance
Organogenesis reported a decline in advanced wound-care revenue during Q1, driven by reduced reimbursements and soft procedure volumes. Management cited payer negotiations and supply-chain constraints as primary headwinds, with adjusted EBITDA contracting on the weaker top line.
2. Peer Comparison
By contrast, Integra LifeSciences grew first-quarter revenue 2.4% to $391.9 million with adjusted EPS up to $0.54, while Bioventus posted a 7% revenue gain to $132.1 million and doubled adjusted EPS to $0.15. The divergence underscores ORGO’s challenges amid stable reimbursement and disciplined execution at rivals.
